VivoSeq
Other

Visual Impairment

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Visual Impairment is an early-stage landscape with 0 programs across 2 companies. The most active players are Outlook Therapeutics, Inc., Bayer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

Outlook Therapeutics, Inc.

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Active, not recruiting2 · 40%
Not yet recruiting2 · 40%
Completed1 · 20%

Clinical Trials

Trial Activity

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Completed·OOutlook Therapeutics, Inc.·Phase 3·NCT04516278·195 enrolled
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Active, not recruiting·OOutlook Therapeutics, Inc.·Phase 3·NCT05112861·120 enrolled
A Cross-Sectional Survey of Global Priority Sensory Impairment Indicators Among People Aged 65 Years and Older in Xinxing County
Not yet recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT07694505·2,854 enrolled
An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in DME and nAMD in a Real-world Setting
Active, not recruiting·Bayer logoBayer·N/A·NCT06075147·2,500 enrolled
Assessment of Caries Impacts and Experiences in a Visually Impaired Versus Sighted Pediatric Population Using a Caries-Specific Quality-of-Life Questionnaire: A Comparative Cross-sectional Study
Not yet recruiting·CCairo University·N/A·NCT07665047·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)